Advertisement
AZN vs BIIB
Which Stock Would AI Choose? AstraZeneca (AZN) vs. Biogen (BIIB) Stock Comparison
Key Takeaways
- AZN has delivered consistent revenue growth driven by its oncology portfolio, with Q1 2026 total revenue rising 8% year-over-year.
- BIIB faces near-term pressure from declining legacy multiple sclerosis product sales ahead of its Q2 2026 earnings release.
- Both stocks operate in the biopharmaceutical sector but differ in scale, with AZN maintaining a larger market capitalization and broader global presence.
- Recent market activity shows AZN trading near $169 with modest year-to-date gains, while BIIB trades near $202 amid pipeline updates in neurology.
- Analyst sentiment remains generally constructive for both, though AZN benefits from recent regulatory approvals in oncology.
- Relative performance highlights trade-offs between established growth drivers at AZN and emerging pipeline catalysts at BIIB.
Introduction
This comparison examines AZN (AstraZeneca PLC) and BIIB (Biogen Inc.), two established players in the biopharmaceutical industry. The analysis focuses on recent performance trends, business fundamentals, and market positioning to assist institutional investors, active traders, and portfolio managers evaluating exposure within the healthcare sector. Readers seeking objective data on relative momentum, sector-specific catalysts, and operational contrasts will find this overview relevant for informed decision-making in current market conditions.
AZN Overview and Recent Performance
AstraZeneca PLC develops and commercializes medicines in oncology, rare diseases, cardiovascular, renal, metabolism, and respiratory areas. In recent market activity, the stock has traded near $169, reflecting modest year-to-date gains amid broader sector dynamics. Performance has been supported by double-digit growth in oncology sales and regulatory progress, including European Union approval for a new cancer treatment. Recent weeks have featured earnings that exceeded expectations on core earnings per share despite a minor revenue shortfall, alongside some pressure from insider activity and debt considerations. Sentiment has remained generally stable, anchored by the company’s diversified pipeline and global commercial reach.
BIIB Overview and Recent Performance
Biogen Inc. focuses on therapies for neurological and neurodegenerative diseases, with key products in multiple sclerosis and Alzheimer’s disease. The stock has recently traded near $202, showing resilience within a 52-week range that extends from the mid-120s to above 219. Recent weeks have included clinical data presentations on Alzheimer’s treatments at major medical conferences, highlighting real-world outcomes and pipeline progress. Performance has been influenced by expectations surrounding the upcoming Q2 2026 earnings report, where analysts anticipate pressure from legacy product declines offset by newer offerings. Market sentiment reflects both the challenges of established franchises and interest in ongoing research and development initiatives.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing automated trading strategies from its extensive library of hundreds of AI Trading Bots that cover thousands of different tickers. Only those bots demonstrating the strongest alignment with prevailing market conditions receive placement in this trending section. Available bots span diverse trading styles, timeframes, and performance metrics, including annualized returns that have ranged from approximately 50% to over 140% in select backtested or simulated scenarios, along with statistics such as Sharpe ratios, profit factors, and drawdown measures. Each robot applies distinct strategies and ticker sets, enabling users to review detailed performance data before considering any implementation. Explore the full selection on the Trending AI Robots page for current options suited to varying objectives.
Head-to-Head Comparison
AZN operates at a larger scale with broader therapeutic diversification compared with BIIB’s more concentrated focus on neurology. Growth drivers differ markedly: AZN benefits from sustained oncology momentum and recent regulatory wins, while BIIB emphasizes pipeline advancement in Alzheimer’s and related areas amid legacy product headwinds. Recent momentum has favored AZN through earnings resilience, whereas BIIB contends with anticipated near-term earnings compression. Risk factors include regulatory and competitive pressures for both, though AZN’s global footprint may provide relative stability versus BIIB’s higher dependence on specific clinical readouts. Market sentiment appears more anchored for AZN in the current environment, while BIIB offers potential upside tied to successful pipeline execution.
Tickeron AI Verdict
Based on observable factors including trend consistency in revenue growth, earnings stability, and positive regulatory catalysts, Tickeron’s AI models currently assign a higher probabilistic weighting to AZN over BIIB in the near term. AZN’s broader diversification and recent performance metrics provide a more consistent profile relative to BIIB’s exposure to upcoming earnings variability and legacy product transitions. This assessment remains probabilistic and subject to evolving market data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZN is a Buy and BIIB is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZN’s FA Score shows that 2 FA rating(s) are green whileBIIB’s FA Score has 1 green FA rating(s).
- AZN’s FA Score: 2 green, 3 red.
- BIIB’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZN’s TA Score shows that 5 TA indicator(s) are bullish while BIIB’s TA Score has 5 bullish TA indicator(s).
- AZN’s TA Score: 5 bullish, 5 bearish.
- BIIB’s TA Score: 5 bullish, 4 bearish.
Price Growth
AZN (@Pharmaceuticals: Major) experienced а +0.22% price change this week, while BIIB (@Pharmaceuticals: Major) price change was +0.38% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.41%. For the same industry, the average monthly price growth was -2.13%, and the average quarterly price growth was +3.17%.
Reported Earning Dates
AZN is expected to report earnings on Oct 30, 2026.
BIIB is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.41% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| AZN | BIIB | AZN / BIIB | |
| Capitalization | 264B | 30B | 880% |
| EBITDA | 20.4B | 2.14B | 954% |
| Gain YTD | 84.532 | 15.319 | 552% |
| P/E Ratio | 25.40 | 36.05 | 70% |
| Revenue | 61.4B | 10B | 614% |
| Total Cash | 4.97B | 1.29B | 387% |
| Total Debt | 32.2B | 8.36B | 385% |
AZN | BIIB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 10 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 11 Undervalued | 81 Overvalued | |
PROFIT vs RISK RATING 1..100 | 15 | 100 | |
SMR RATING 1..100 | 44 | 87 | |
PRICE GROWTH RATING 1..100 | 44 | 44 | |
P/E GROWTH RATING 1..100 | 60 | 5 | |
SEASONALITY SCORE 1..100 | 55 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AZN's Valuation (11) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (81) in the Biotechnology industry. This means that AZN’s stock grew significantly faster than BIIB’s over the last 12 months.
AZN's Profit vs Risk Rating (15) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that AZN’s stock grew significantly faster than BIIB’s over the last 12 months.
AZN's SMR Rating (44) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (87) in the Biotechnology industry. This means that AZN’s stock grew somewhat faster than BIIB’s over the last 12 months.
AZN's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as BIIB (44) in the Biotechnology industry. This means that AZN’s stock grew similarly to BIIB’s over the last 12 months.
BIIB's P/E Growth Rating (5) in the Biotechnology industry is somewhat better than the same rating for AZN (60) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew somewhat faster than AZN’s over the last 12 months.
| AZN | BIIB | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 47% | 4 days ago 81% |
| Stochastic ODDS (%) | 4 days ago 43% | 4 days ago 56% |
| Momentum ODDS (%) | 4 days ago 60% | 4 days ago 74% |
| MACD ODDS (%) | 4 days ago 62% | 4 days ago 56% |
| TrendWeek ODDS (%) | 4 days ago 57% | 4 days ago 58% |
| TrendMonth ODDS (%) | 4 days ago 46% | 4 days ago 72% |
| Advances ODDS (%) | 6 days ago 58% | 6 days ago 57% |
| Declines ODDS (%) | 4 days ago 45% | 4 days ago 71% |
| BollingerBands ODDS (%) | 4 days ago 53% | 6 days ago 77% |
| Aroon ODDS (%) | 5 days ago 51% | 4 days ago 51% |
Advertisement
AZN and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZN has been loosely correlated with BIIB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AZN jumps, then BIIB could also see price increases.
| Ticker / NAME | Correlation To AZN | 1D Price Change % | ||
|---|---|---|---|---|
| AZN | 100% | -0.99% | ||
| BIIB - AZN | 48% Loosely correlated | -2.40% | ||
| LLY - AZN | 44% Loosely correlated | -0.53% | ||
| GILD - AZN | 39% Loosely correlated | -0.82% | ||
| NVS - AZN | 30% Poorly correlated | -1.45% | ||
| MRK - AZN | 28% Poorly correlated | +0.32% | ||
More | ||||
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with AMGN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | -2.40% | ||
| AMGN - BIIB | 49% Loosely correlated | -0.64% | ||
| AZN - BIIB | 49% Loosely correlated | -0.99% | ||
| PFE - BIIB | 48% Loosely correlated | +0.40% | ||
| MRK - BIIB | 47% Loosely correlated | +0.32% | ||
| BMY - BIIB | 44% Loosely correlated | +0.69% | ||
More | ||||